Clinical Trials Logo

Transposition of Great Vessels clinical trials

View clinical trials related to Transposition of Great Vessels.

Filter by:

NCT ID: NCT01153776 Completed - Clinical trials for Arterial Switch Operation

CT Coronary Angiography After Arterial Switch Operation

SCANTGV
Start date: September 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to find a non-invasive alternative (with using ECG gated 64-slice CT angiography) to invasive coronary angiography for detecting coronary lesions in patients who had undergone arterial switch operation for transposition of the great arteries

NCT ID: NCT01120106 Completed - Clinical trials for Low Cardiac Output Syndrome

Levosimendan Administration in Neonates With Transposition of the Great Arteries

Start date: January 2009
Phase: Phase 2
Study type: Interventional

Calcium sensitizer drugs such as Levosimendan may exert anti-ischemic effect in addition to positive inotropic and anti-stunning effects mediated by the opening of ATP-sensitive potassium (KATP) channels. The aim of the study is to test the myocardial protection effect of peri-operative iv infusion of Levosimendan in a cohort of neonates affected by transposition of the great arteries undergoing surgical correction by arterial switch.

NCT ID: NCT00837603 Completed - Clinical trials for Transposition of Great Vessels

Physical Training in Transposition of the Great Arteries

TrainingTGA
Start date: February 2009
Phase: N/A
Study type: Interventional

In transposition patients after atrial switch operation, the morphological right ventricle serves as the systemic ventricle. These patients often develop signs of heart failure. It is not known, whether physical training can safely be recommended in these patients- like heart failure guidelines recommend training in patients with normal anatomy. Furthermore it is not known, whether these TGA-patients benefit from training with respect to cardiopulmonary exercise capacity.

NCT ID: NCT00703352 Completed - Clinical trials for Transposition of Great Vessels

Eplerenone in Systemic Right Ventricle

EVEDES
Start date: July 2008
Phase: Phase 4
Study type: Interventional

BACKGROUND: There is no clinical evidence supporting medical treatment for the failing systemic right ventricle in patients with transposition of the great vessels with atrial switch. Cardiac magnetic resonance studies have shown a significant degree of myocardial fibrosis in right ventricles in the systemic position, which predisposes to systolic and diastolic dysfunction. Aldosterone is a widely recognized neurohormonal marker involved in the formation of myocardial fibrosis and the treatment with aldosterone antagonists has shown a decrease in ventricular mass in hypertensive patients, presumably related to reduction of myocardial fibrosis. HYPOTHESIS: Low dose of eplerenone, a selective mineralocorticoid receptor blocker, in patients with systemic right ventricle can reduce the ventricular mass by means of a reduction in myocardial fibrosis, resulting in improved systolic function. PATIENTS AND METHODS: Randomized, double blind, parallel clinical trial comparing eplerenone (50mg daily) with placebo. Study population: Adult patients (>18 years) diagnosed with repaired transposition of the great arteries with atrial switch (Senning or Mustard techniques) routinely followed at a tertiary referral center. Duration: 12 months. Outcomes: Right ventricular mass, myocardial fibrosis mass and ejection fraction assessed by cardiac magnetic resonance.

NCT ID: NCT00513240 Completed - Clinical trials for Congenital Heart Disease

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

Start date: September 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Brain problems occur in neonatal open heart surgery with a frequency of 20-70%, seen on neurological examination, brain imaging such as magnetic resonance imaging (MRI), or long term development problems such as learning disorders and hyperactivity syndromes. This study aims to determine if erythropoetin, a natural hormone made in the body, protects the brain from damage when given in high doses before and during neonatal open heart surgery. We will use brain MRI, brain wave tests (EEG), neurological examination, and long term developmental outcome testing to see if erythropoetin is better than salt water injection (placebo) in protecting the brain.

NCT ID: NCT00412685 Completed - Tetralogy of Fallot Clinical Trials

Myocardial Contrast Echocardiography in Congenital Heart Disease

Start date: August 2006
Phase: N/A
Study type: Observational

Patients with congenital heart disease in whom the right ventricle is exposed to pressure or volume overload show progressive systolic dysfunction of the right ventricle, the fact of which conveys substantial morbidity and mortality. The aim of this study is to investigate the myocardial perfusion in these patients by myocardial contrast echocardiography (MCE) in order to determine whether disturbed blood flow plays a role in the development of right ventricular systolic dysfunction.

NCT ID: NCT00374088 Completed - Clinical trials for Congenital Heart Disease

N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)

Start date: February 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether intravenous N-acetylcysteine (also known as Acetadote), an antioxidant medication that has been used for years to treat Tylenol overdose, helps prevent heart dysfunction in the early postoperative period following congenital heart surgery. Children undergoing major heart surgery, such as the arterial switch operation, routinely develop temporary heart dysfunction in the first 12-24 hours after surgery. This heart dysfunction may be severe and contributes to an increased risk for death or prolonged hospitalization. Current standard treatments include intravenous medications such as dopamine, epinephrine, and vasopressin that support your child's blood pressure and heart function. Unfortunately, high doses of these medications have the potential to cause severe side effects including loss of fingers and toes, liver and kidney dysfunction, and heart rhythm abnormalities. Our goal is to find a way to reduce heart dysfunction after major heart surgery in order to promote a smoother postoperative period, and reduce the risks associated with heart operations in children.

NCT ID: NCT00313352 Completed - Clinical trials for Congenital Disorders

Effects of Beta-adrenergic in Adults w/Transposition of Great Arteries on Systemic Ventricular Function

Start date: January 1997
Phase: N/A
Study type: Observational

The purpose of this chart review study is to examine the effects of beta -adrenergic blocking agents on systemic ventricular dimensions, systemic atrioventricular valve function and exercise tolerance in patients with transposition of the great arteries (TGA) and systemic ventricular dysfunction.

NCT ID: NCT00199771 Completed - Clinical trials for Heart Defects, Congenital

Hypertonic Saline Dextran in Pediatric Cardiac Surgery

Start date: June 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether infusion of hypertonic saline dextran attenuates the inflammatory response and the water overload, during and after major cardiac surgery in small children.

NCT ID: NCT00006183 Completed - Clinical trials for Cardiovascular Diseases

Comparison of Hematocrit Levels in Infant Heart Surgery

Start date: July 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effects of diluted hematocrit (HCT) levels of 35% versus 25% during hypothermic cardiopulmonary bypass (CPB) in infants with d-transposition of the great arteries, a malformation of the heart vessels.